



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Background

Cas9 (*Streptococcus pyogenes* CRISPR associated protein 9) is an endonuclease enzyme that, when recruited to a specific DNA sequence by the sgRNA (single guide RNA), introduces a double stranded break into the DNA. This double stranded break is repaired in mammalian cells either through Non-Homologous End Joining or Homologous Recombination. Non-Homologous End Joining often results in the deletion or insertion of several base pairs at the cut site, which, when resulting in a frameshift, causes the functional inactivation of the targeted gene. Cas9-expressing HeLa cells can be transduced or electroporated with sgRNA targeting a gene of interest to quickly generate knock-out cell pools or cell lines.

Application

1. Quickly generating knock-out cell pools or cell lines in HeLa cells.
2. Implementing sgRNA screens in Cas9-expressing HeLa cells.

Materials Provided

Components	Format
2 vials of frozen cells	Each vial contains 2×10^6 cells in 1 ml of 10% DMSO

Host Cell

HeLa human cervical cancer cell line. Adherent epithelial cells.

Mycoplasma Testing

This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.

Materials Required but Not Supplied

These materials are not supplied with this cell line but are necessary for cell culture and cellular assays. BPS Bioscience reagents systems are validated and optimized for use with this cell line and are highly recommended for best results. Media components are provided in the Media Formulations section.

Materials Required for Cell Pool Culture

Name	Ordering Information
Thaw Medium 1	BPS Bioscience #60187
Growth Medium 1N	BPS Bioscience #79801

Storage Conditions

Cells will arrive upon dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.

License Disclosure

Visit bpsbioscience.com/license for the label license and other key information about this product.

Troubleshooting Guide

For all questions, please email support@bpsbioscience.com.

Media Formulations

For best results, it is *highly recommended* to use these validated and optimized media from BPS Bioscience. To formulate a comparable but not BPS validated media, formulation components can be found below.



Note: Thaw Medium does *not* contain selective antibiotics. However, Growth Medium *does* contain selective antibiotics, which are used for maintaining cell lines over many passages. Cells should be grown at 37°C with 5% CO₂ using Growth Medium 1N.

Media Required for Cell Pool Culture

Thaw Medium 1 (BPS Bioscience #60187):

DMEM medium (Hyclone #SH30243.01) supplemented with 10% FBS (Life technologies #26140-079), and 1% Penicillin/Streptomycin (Hyclone #SV30010.01).

Growth Medium 1N (BPS Bioscience # 79801):

Thaw Medium 1 (BPS Bioscience, #60187) plus 0.25 µg/mL Puromycin (Invivogen, #ant-pr-1) to ensure recombinant expression.

Cells should be grown at 37°C with 5% CO₂ using Growth Medium 1N to ensure recombinant expression is maintained.

Recommended Culture Conditions

Frozen Cells:

1. Prepare T-75 culture flask with 20 ml of pre-warmed Thaw Medium 1 (**no Puromycin**).
2. Quickly thaw cells in a 37°C water bath with constant and slow agitation.
3. After cleaning the outside of the vial with 70% ethanol, immediately transfer the entire content to Thaw Medium 1 (**no Puromycin**). Avoid pipetting up and down, and gently rock the flask to distribute the cells.
4. Incubate the cells in a humidified 37°C incubator with 5% CO₂.
5. 24-48 hours after incubation, change to fresh Growth Medium 1N (**contains Puromycin**), without disturbing the attached cells.
6. Continue to change medium every 2-3 days until cells reach desired confluency.

Subculture:

1. When cells reach 90% confluency, remove Growth Medium 1N and wash twice with PBS (without Magnesium or Calcium).
2. Treat cells with 2-3 ml of 0.25% Trypsin/EDTA and incubate for 2-3 minutes at 37°C.
3. After confirming cell detachment by light microscopy, add 10 mL pre-warmed Growth Medium 1N and gently pipette up and down to dissociate cell clumps.
4. Transfer cells to a 15 ml conical tube and centrifuge at 200 x g for 5 minutes.
5. Remove the medium and resuspend cells in 10 ml pre-warmed Growth Medium 1N.
6. Dispense 1 mL of the cell suspension into a new T75 flask containing pre-warmed 9 ml Growth Medium 1N (a subcultivation ratio of 1:2 to 1:10 is recommended).

7. Incubate cells in a humidified 37°C incubator with 5% CO₂.

Cryopreservation:

1. When cells have reached 90% confluency, use trypsin to remove cells from plate as above, spin cells and remove medium from the pellet.
2. Resuspend the cells in freezing medium (10% DMSO in FBS).
3. Freeze cells using a reduced rate freezing box (-0.5°C to -1°C per minute) down to -80°C, then move cells to liquid nitrogen for long term storage.



Cells have been demonstrated to be stable for at least 15 passages; BPS recommends preparing frozen stocks early so cells are not used beyond passage 20.

Validation Data




Figure 1. Flow cytometry analysis of intracellular expression of Cas9 in HeLa cell pool. Cells were stained with PE-labeled anti-FLAG antibody (BioLegend, #637309) and analyzed by flow cytometry. The parental HeLa cells are shown in green, the Cas9-expressing HeLa cell pool (BPS Bioscience, #78161) is shown in blue.

Vector and Sequence

Streptococcus pyogenes Cas9, including a C-terminal FLAG tag, was transduced via lentivirus (BPS Bioscience, #78066).

MDKKYSIGLDIGTNSVGVAVITDEYKVPSSKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEFSN
 EMAKVDDSFHRLLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNP
 DNSDVKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRLENLIAQLPGEKKNLFGNLIALSGLTPNFKSNFDLAEDAKL
 QLSKDTYDDDLNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPKEYKEIFF
 DQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKNLREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLKDNREKI
 EKILTFRIPYYVGPLARGNSRFAMTRKSEETITPWNFEVVDKGASAQSFIERMTNFDKNLPNEKVLPHKSLLEYFTVYNELTKV
 KYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDIL
 EDIVLTLTFEDREMIEERLKYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDFANRNFQMQLIHDDSLT
 FKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGI
 KELGSQILKEHPVENTQLQNEKLYLYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEE
 VVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRLVETRQITKHVAQILD SRMNTKYDENDKLIREVKVITLKS
 KLVSDFRKDFQFYKVINNYHHAHDAYLNAVVG TALIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATAKYFFYSNIMNFFK
 TEITLANGEIRKPLIETNGETGEIVWDKGRDFATVRKVL SMPQVNIVKKEVQTGGFSKESILPKRNSDKLIARKKDWDPKYYGGF
 DSPTVAYSVLVVAKVEKGSKLLKSVKELLGITIMERSSEFNPIDFLEAKGYKEVKKDLIILPKYSLFELENGRKRMLASAGELQKG
 NELALPSKYVNFLYLASHYEKLGSPEDNEQQLFVEQHKHYLDEIIEQISEFSKRVLADANLDKVL SAYNKHRDKPIREQAENIIHL
 FTLNLGAPAAFYFDTTIDRKRYTSTKEVL DATLIHQISITGLYETRIDLSQLGGDKRPAATKKAGQAKKKKDYKDDDD

Related Products

<i>Products</i>	<i>Catalog #</i>	<i>Size</i>
Cas9 Lentivirus (puromycin selection)	78066	500 µl x 2
Cas9, His-tag (<i>S. pyogenes</i>)	100206-1	50 µg
Thaw Medium 1	60187	100 ml
Growth Medium 1N	79801	500 ml

Notes

The CRISPR/CAS9 technology is covered under numerous patents, including U.S. Patent Nos. 8,697,359 and 8,771,945, as well as corresponding foreign patents applications, and patent rights.